News reaching our desk is that the stride to access Mpox vaccine doses, for monkeypox just got easier. Uganda is set to receive 10,000 vaccine doses next week, starting 20 January 2025. This donation has been facilitated by the U.S. government through the Africa Centres for Disease Control and Prevention (Africa CDC). It aims to strengthen the country’s efforts against the viral outbreak.
Also read about HMPV virus
When did the first Mpox case happen in Uganda?
Uganda reported its first cases of Mpox in July 2024, marking the virus’s entry during a broader outbreak in Central and East Africa. The World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern in August 2024, underscoring the global health implications. By November 2024, Uganda had documented 359 cases across 35 districts, with one confirmed death.
What has the government said about the Mpox vaccine availability?
Health Minister Jane Ruth Aceng announced that mass vaccination campaigns are slated to begin in February 2025, prioritizing regions with active transmission. She emphasized that the mpox vaccine is crucial in curbing the disease’s spread.
Dr. Mary Boyd, speaking at the Uganda Media Centre, reassured the public about the vaccine’s safety, citing endorsements from global health authorities. She also highlighted additional U.S. support, including 10,000 testing kits to enhance Mpox detection and treatment capacities.
The Ministry of Health urges the public to remain vigilant and adhere to preventive measures as preparations for the vaccination rollout continue. Preventive strategies include avoiding close contact with individuals exhibiting Mpox symptoms, practicing good hand hygiene, and isolating infected persons to prevent transmission.
Why the country needed mpox vaccine doses quickly
The Mpox outbreak has significantly impacted Central and East Africa, with the Democratic Republic of the Congo reporting over 18,000 cases and 629 deaths since September 2023. The virus has also spread to neighboring countries, including Burundi, Rwanda, and Kenya. The outbreak consists of two separate sub-variants, with one having a novel mutation that complicates detection with standard assays.
Despite the challenges, there are signs of progress. Improvements in surveillance, case detection, infection prevention, and patient care have been observed. However, countries like the Democratic Republic of the Congo continue to face significant hurdles due to limitations in diagnostics and logistics.
Uganda’s proactive measures, including the upcoming vaccination campaign, reflect a commitment to controlling the Mpox outbreak and safeguarding public health. The collaboration with international partners to access over 10,000 mpox vaccine doses underscores the importance of a united front in addressing global health challenges.
